Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3547926 Alone and in Combination in Advanced Hepatocellular Carcinoma
NCT06764316Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Feb 2025
- Primary completion
- Jul 2029
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of BAY 3547926 in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events up to 60 months, Recommended Safe and Active Dose up to 60 months and 4 more. Started Feb 2025; status: recruiting.
02
Drugs
BAY 3547926
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06764316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764316.